Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL1583028 | 0.97 | ALDH1A1 (0.56) | ALDH1A1CXCR4SMN1; SMN2 | |
| Pyrrolidine SCHEMBL28317841 | 0.97 | ALDH1A1 (0.47) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL1288276 | 0.94 | ALDH1A1 (0.53) | ALDH1A1CXCR4SMN1; SMN2 | |
| Pyrrole SCHEMBL6427563 | 0.93 | — | — | |
| Pyrrole SCHEMBL28257456 | 0.90 | CXCR4 (0.56) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Pyrrole SCHEMBL28636726 | 0.89 | — | — | |
| Piperazine SCHEMBL20360553 | 0.86 | HIF1A (0.46) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL28257898 | 0.86 | HIF1A (0.46) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL27867168 | 0.83 | HIF1A (0.43) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A | |
| Piperazine SCHEMBL28087044 | 0.83 | HIF1A (0.43) | CXCR4SMN1; SMN2HIF1AMAPTPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4051711-A2 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| EP-4028494-A1 | REDUCING FRICTION IN COMBUSTION ENGINES THROUGH FUEL ADDITIVES | Chevron Oronite Company LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021087368-A2 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | Magenta Therapeutics, Inc. (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021048677-A1 | REDUCING FRICTION IN COMBUSTION ENGINES THROUGH FUEL ADDITIVES | CHEVRON ORONITE COMPANY LLC (US) | 2021-03-18 | — | — | WO | disclosed |
| EP-2600720-B1 | PESTICIDAL TREATMENT COMPOSITIONS | GOWAN COM INTERNAC E SERVICOS LIMITADA (PT) | 2014-11-26 | — | — | EP | disclosed |
| EP-1530582-A4 | DIAGNOSIS OF KIDNEY DAMAGE AND PROTECTION AGAINST SAME | UNIV OHIO (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1824518-A2 | DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON PROTEINS DIFFERENTIALLY EXPRESSED IN SERUM | Ohio University (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007002830-A2 | DIAGNOSIS OF AND PROTECTION FROM HYPERINSULINEMIA AND TYPE II DIABETES | OHIO UNIVERSITY (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1732582-A2 | DIAGNOSIS OF HYPERINSULINEMIA AND TYPE II DIABETES AND PROTECTION AGAINST SAME BASED ON GENES DIFFERENTIALLY EXPRESSED IN MUSCLE CELLS | Ohio University (US) | 2006-12-20 | — | — | EP | disclosed |
| CN-1281591-C | 4-aminopyridinecarboxylates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2006-10-25 | — | — | CN | disclosed |
| WO-2002004956-A9 | METHOD OF IDENTIFYING CONFORMATION-SENSITIVE BINDING PEPTIDES AND USES THEREOF | KARO BIO USA INC (US) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002040631-A2 | DIPEPTIDE SERYL-HISTIDINE AND RELATED OLIGOPEPTIDES CLEAVE DNA, PROTEIN, AND A CARBOXYL ESTER | OHIO UNIVERSITY (US) | 2002-05-23 | — | — | WO | disclosed |
| WO-2002004956-A2 | METHOD OF IDENTIFYING CONFORMATION-SENSITIVE BINDING PEPTIDES AND USES THEREOF | KARO BIO USA, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1073891-A2 | METHOD OF PREDICITING RECEPTOR MODULATING ACTIVITY | Karo Bio USA, Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-1002235-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | Novalon Pharmaceutical Corporation (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999054728-A2 | METHOD OF PREDICTING RECEPTOR MODULATING ACTIVITY | KARO BIO USA, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0937253-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | Novalon Pharmaceutical Corporation (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999006839-A1 | METHOD OF IDENTIFYING AND DEVELOPING DRUG LEADS | NOVALON PHARMACEUTICAL CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998019162-A9 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | — | 1998-07-09 | — | — | WO | disclosed |
| WO-1998019162-A1 | IDENTIFICATION OF DRUGS USING COMPLEMENTARY COMBINATORIAL LIBRARIES | NOVALON PHARMACEUTICAL CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |